Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149514 (bronchitis)
 6,902 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Relationship between carcinoid tumourlets and chronic pulmonary hypoxia was studied on a group of 29 patients coming to necropsy (25 cases) in the last 25 years or surgically treated (4 cases) for non-neoplastic pulmonary lesions. All tumourlets expressed the argyrophilia and were immunoreactive for neurone-specific enolase. Pulmonary hypoxia was studied according to the presence of chronic bronchitis, emphysema and microscopical signs of hypoxic arteriopathy. Cigarette smoking was an additional criterion. The results indicated a strong relationship between tumourlets and chronic pulmonary hypoxia. 79% of patients with tumourlets have had the emphysema and in 41% of examined cases with this lesion the chronic bronchitis was diagnosed. The hypoxic arteriopathy was present in 48% of subjects with emphysema and 27% of cases with bronchitis. It was found in the same number of patients with both the examined lung diseases. On the other hand, the possibility of other cause of neuroendocrine cell hyperplasia was to be considered in 17% of investigated subjects in whom no evidence for the above mentioned relationship was found.
 ...
PMID:[Carcinoid tumorlets and pulmonary hypoxia]. 947 92

The purpose of the study was to investigate significance of the tumor marker pyruvate kinase Tumor M2 (Tu M2-PK), in diagnostics, monitoring of treatment, and evaluation of its effectiveness in patients with lung cancer (LC). This is an isoform of the glycosile enzyme pyruvate kinase, existing as an active dimer and less active tetramer. The expression of the less active form is typical of tumor cells; its blood level can be measured. The subjects of the study were 140 patients with LC of various histologic types. Serum levels of certain tumor markers (Cyfra 21-1, NSE, SCC, and Tu M2-PK) were measured; Tu M2-PK level was determined by ELISA test from ScheBoTech, a two-stage sandwich immunoassay using one type of antibodies. The marker concentration was also determined in 195 healthy volunteers (control group.) The maximum concentration of Tu M2-PK was 12.9 U/ml, determined with 95% specificity. 78% of the patients with small-cell carcinoma, 73% of patients with adenocarcinoma, and 81% of patients with non-small cell lung carcinoma displayed increase of Tu M2-PK serum concentration; this concentration was within normal limits in patients with nonmalignant diseases (e.g. bronchitis or tuberculosis). Thus, patients with lung carcinoma display a pathologic increase of Tu M2-P level. Measurement of Tu M2-P may be useful in patients with suspected LC; this marker may be of greater diagnostic significance than SCC or NSE.
 ...
PMID:[The significance of TU M2-PK tumor marker for lung cancer diagnostics]. 1788 13